Analysts Set Intellia Therapeutics (NTLA) Price Target at $34.40

Shares of Intellia Therapeutics (NASDAQ:NTLA) have been given an average rating of “Buy” by the thirteen ratings firms that are currently covering the stock, MarketBeat reports. Five investment analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $34.40.

Several research firms have recently weighed in on NTLA. BidaskClub upgraded shares of Intellia Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, March 13th. JMP Securities began coverage on shares of Intellia Therapeutics in a research note on Thursday, March 8th. They issued an “outperform” rating for the company. Barclays lifted their target price on shares of Intellia Therapeutics from $33.00 to $46.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 7th. Wedbush reiterated an “outperform” rating and issued a $36.00 target price on shares of Intellia Therapeutics in a research note on Thursday, March 15th. Finally, Leerink Swann reiterated an “outperform” rating on shares of Intellia Therapeutics in a research note on Wednesday, March 14th.

How to Become a New Pot Stock Millionaire

In related news, major shareholder Caribou Biosciences, Inc. sold 550,645 shares of the business’s stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $26.78, for a total transaction of $14,746,273.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jean Francois Formela sold 39,245 shares of the business’s stock in a transaction that occurred on Tuesday, March 20th. The shares were sold at an average price of $23.87, for a total transaction of $936,778.15. The disclosure for this sale can be found here. 3.20% of the stock is currently owned by insiders.



Large investors have recently modified their holdings of the stock. D.A. Davidson & CO. bought a new stake in Intellia Therapeutics during the fourth quarter valued at approximately $323,000. New York State Common Retirement Fund lifted its position in Intellia Therapeutics by 137.4% during the third quarter. New York State Common Retirement Fund now owns 35,848 shares of the company’s stock valued at $891,000 after purchasing an additional 20,748 shares during the last quarter. K.J. Harrison & Partners Inc bought a new stake in Intellia Therapeutics during the fourth quarter valued at approximately $308,000. ARK Investment Management LLC lifted its position in Intellia Therapeutics by 269.2% during the fourth quarter. ARK Investment Management LLC now owns 1,375,149 shares of the company’s stock valued at $26,430,000 after purchasing an additional 1,002,671 shares during the last quarter. Finally, Slow Capital Inc. bought a new stake in Intellia Therapeutics during the fourth quarter valued at approximately $294,000. 58.45% of the stock is owned by institutional investors.

Shares of NTLA traded up $0.35 during trading hours on Friday, hitting $20.51. The company’s stock had a trading volume of 263,607 shares, compared to its average volume of 1,109,570. The company has a market capitalization of $876.92, a price-to-earnings ratio of -10.82 and a beta of 2.83. Intellia Therapeutics has a 52-week low of $11.15 and a 52-week high of $35.99.

Intellia Therapeutics (NASDAQ:NTLA) last posted its earnings results on Wednesday, March 14th. The company reported ($0.61) earnings per share for the quarter, missing the consensus estimate of ($0.45) by ($0.16). The business had revenue of $6.70 million during the quarter, compared to analysts’ expectations of $8.84 million. Intellia Therapeutics had a negative return on equity of 31.27% and a negative net margin of 258.62%. Intellia Therapeutics’s revenue for the quarter was up 19.6% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.31) EPS. research analysts expect that Intellia Therapeutics will post -2.27 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This article was published by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this article on another website, it was stolen and reposted in violation of international trademark and copyright laws. The correct version of this article can be accessed at https://stocknewstimes.com/2018/04/25/analysts-set-intellia-therapeutics-ntla-price-target-at-34-40.html.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs.

Analyst Recommendations for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply